1. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010; 58:258-266.
2. Miyara M, Wing K, Sakaguchi S. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J Allergy Clin Immunol 2009; 123:749-755.
3. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 1999; 94:1899-1905.
4. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G. Decreased expression of CCR5 on the NK cells in occult HBV infected patients. Lab Med 2010; 41:735-738.
5. Jin Q, Agrawal L, Meyer L, Tubiana R, Theodorou I, Alkhatib G. CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects. J Viro. 2008; 82:2418-2426.
6. Singh H, Sachan R, Jain M, Mittal B. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res 2008; 17:87-91.
7. Nahon P, Sutton A, Rufat P, Simon C, Trinchet JC, Gattegno L, et al. Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 2008;14:713-719.
8. Ghorban K, Dadmanesh M, Hassanshahi G, Momeni M, Zare-Bidaki M, Arababadi MK, et al. Is the CCR5 Delta 32 mutation associated with immune system-related diseases? Inflammation 2013; 36:633-642.
9. Guerini FR, Delbue S, Zanzottera M, Agliardi C, Saresella M, Mancuso R, et al. Analysis of CCR5, CCR2, SDF1 and RANTES gene polymorphisms in subjects with HIV-related PML and not determined leukoencephalopathy. Biomed Pharmacother 2008; 62:26-30.
10. Abousaidi H, Vazirinejad R, Arababadi MK, Rafatpanah H, Pourfathollah AA, Derakhshan R, et al. Lack of association between chemokine receptor 5 (CCR5) delta32 mutation and pathogenesis of asthma in Iranian patients. South Med J 2011; 104:422-425.
11. Chang HY, Ahn SH, Kim DY, Shin JS, Kim YS, Hong SP, et al. Association between CCR5 promoter polymorphisms and hepatitis B virus infection. Korean J Hepatol 2005; 11:116-124.
12. Al-Abdulhadi SA, Al-Rabia MW. Linkage and haplotype analysis for chemokine receptors clustered on chromosome 3p21.3 and transmitted in family pedigrees with asthma and atopy. Ann Saudi Med 2010; 30:115-122.
13. Lehner T. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol 2002; 23:347-351.
14. Ahmadabadi BN, Hassanshahi G, Khoramdelazad H, Mirzaei V, Sajadi SMA, Hajghani M, et al. Down-regulation of CCR5 expression on the peripheral blood CD8+ T cells of South-Eastern Iranian patients with chronic hepatitis B infection. Inflammation 2013; 36:136-140.
15. Song JK, Park MH, Choi DY, Yoo HS, Han SB, Yoon do Y, et al. Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and upregulation of IL-1Ra in melanoma model. PLoS One 2012; 7:e33747.
16. Kuipers HF, Biesta PJ, Montagne LJ, van Haastert ES, van der Valk P, van den Elsen PJ. CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. Blood 2008; 112:1610-1619.
17. Blanpain C, Libert F, Vassart G, Parmentier M. CCR5 and HIV infection. Receptors Channels 2002; 8:19-31.
18. Sorce S, Myburgh R, Krause KH. The chemokine receptor CCR5 in the central nervous system. Prog Neurobiol 2011; 93:297-311.
19. Wong M, Uddin S, Majchrzak B, Huynh T, Proudfoot AE, Platanias LC, et al. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells. J Biol Chem 2001; 276:11427-11431.
20. Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM, Ghaderi A. The frequency of CCR5Delta32 and CCR2-64I in southern Iranian normal population. Immunol Lett 2005; 96:277-281.
21. Azmandian J, Mandegary A, Saber A, Torshabi M, Etminan A, Ebadzadeh MR, et al. Chemokine receptor 2-V64I and chemokine receptor 5-Delta32 polymorphisms and clinical risk factors of delayed graft function and acute rejection in kidney transplantation. Iran J Kidney Dis 2012; 6:56-62.
22. Khademi B, Razmkhah M, Erfani N, Gharagozloo M, Ghaderi A. SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res 2008; 14:45-50.
23. Khorram Khorshid HR, Manoochehri M, Nasehi L, Ohadi M, Rahgozar M, Kamali R. CCR2-64i and CCR5 Delta32 polymorphisms in patients with late-onset Alzheimer's disease; a study from Iran. Iran J Basic Med Sci 2012; 15:937-944.
24. Mojtahedi Z, Ahmadi SB, Razmkhah M, Azad TK, Rajaee A, Ghaderi A. Association of chemokine receptor 5 (CCR5) delta32 mutation with Behcet's disease is dependent on gender in Iranian patients. Clin Exp Rheumatol 2006; 24:S91-94.
25. M. AMS, ؟؟Rezazadeh M, Gharesouran j, Yeghaneh T, Farhoudi M, Ayromlou H, et al. Association of
CCR2 gene but not CCR5 gene polymorphisms with Alzheimer's disease. J Sci Islam Rep Iran 2011; 22:111-116.
26. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Mohit M, Hajghani M, et al. Peripheral blood CD8+ T cells CCR5 expression and its D 32 mutation in Iranian patients with occult hepatitis B infection. LabMed 2010; 41:226-230
27. Khorramdelazad H, Hakimizadeh E, Hassanshahi G, Rezayati M, Sendi H, Arababadi MK. CCR5 D 32 mutation is not prevalent in iranians with chronic HBV infection. J Med Virol 2013; 9999:1-5.
28. Arababadi MK, Naghavi N, Hassanshahi G, Mahmoodi M. Is CCR5-Delta32 mutation associated with diabetic nephropathy in type 2 diabetes? Ann Saudi Med 2009; 29:413.
29. Arababadi MK, Hassanshahi G, Azin H, Salehabad VA, Araste M, Pourali R, et al. No association between CCR5 D 32 mutation and multiple sclerosis in patients of south-eastern of Iran. LabMed 2010; 1:31-33.
30. Shahbazi M, Ebadi H, Fathi D, Roshandel D, Mahamadhoseeni M, Rashidbaghan A, et al. CCR5-delta 32 allele is associated with the risk of developing multiple sclerosis in the Iranian population. Cell Mol Neurobiol 2009; 29:1205-1209.
31. Abdi R, Tran TB, Sahagun-Ruiz A, Murphy PM, Brenner BM, Milford EL, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002; 3:754-758.
32. Omrani MD, Mokhtari MR, Tagizadae A, Bagheri M, Ahmad-Poor P. Association of CCR5-59029 A/G and CCR2-V64I variants with renal allograft survival. Iran J Immunol 2008; 5:201-206.